JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants
about
Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabGenetic variants are major determinants of CSF antibody levels in multiple sclerosis.Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance.Amino Acid Variation in HLA Class II Proteins Is a Major Determinant of Humoral Response to Common VirusesNeuropathology of JC virus infection in progressive multifocal leukoencephalopathy in remissionImmunology of progressive multifocal leukoencephalopathy.Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.Natalizumab treatment of multiple sclerosis: new insights.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologicaStudy of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.Inter- and intralaboratory comparison of JC polyomavirus antibody testing using two different virus-like particle-based assays.Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.
P2860
Q34818048-4C82DE8C-27A8-4B52-8B3B-FA8663668A9FQ35533986-B345DF31-9B3E-4FD8-B697-BFA2A2C30E92Q36153492-934D1F22-C4E2-4118-BFC5-902205A6C895Q36339764-06CAFE4A-065C-4E40-BC6D-74C151A6C5E7Q36527653-8988D951-34ED-4C6B-B31B-287D41148870Q38367755-A3A3E655-F44E-4FAF-A07C-1F74699E9717Q38577593-1E19A114-68E8-41F1-822B-916B7661047FQ38801394-AD6A7A54-F911-4A7F-8840-B6E1A5A8049FQ39046213-8906B025-F872-4425-9A90-F3C15FF49C72Q39048568-CD3F7A24-F58F-409C-B3A4-211ED63C4C16Q40067748-A6723610-AE88-4831-8B67-13D7E18EC498Q40401876-876E9214-114E-498D-B1FE-CDF05F01BC03Q40792696-6E800420-92F8-446E-B3D9-A7A1E8E35FABQ40938497-96A7A446-974D-4407-83BC-ED67A86E5832Q41727049-A51F6DEF-ABE1-4890-9234-19D4F1A54463Q42181572-7575E09F-24CC-464F-9FF2-2105AA744EBDQ49884884-9D496AA1-97D7-4B00-9EF1-90226D7A79EA
P2860
JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
JC polyomavirus infection is s ...... cyte antigen class II variants
@ast
JC polyomavirus infection is s ...... cyte antigen class II variants
@en
type
label
JC polyomavirus infection is s ...... cyte antigen class II variants
@ast
JC polyomavirus infection is s ...... cyte antigen class II variants
@en
prefLabel
JC polyomavirus infection is s ...... cyte antigen class II variants
@ast
JC polyomavirus infection is s ...... cyte antigen class II variants
@en
P2093
P2860
P50
P1433
P1476
JC polyomavirus infection is s ...... cyte antigen class II variants
@en
P2093
Anna Fogdell-Hahn
Annette B Oturai
Bernhard Hemmer
Clemens Warnke
Emilie Sundqvist
Eva Albrecht
Helle Bach Søndergaard
International Multiple Sclerosis Genetics Consortium
Jan Hillert
Tomas Olsson
P2860
P304
P356
10.1371/JOURNAL.PPAT.1004084
P50
P577
2014-04-24T00:00:00Z